Roche, Isis ally to develop Huntington's disease drugs

04/9/2013 | Yahoo

Roche Holding and Isis Pharmaceuticals agreed to collaborate in the development of Huntington's disease drugs using the latter's antisense technology. The partners will initially focus on Isis' lead drug candidate designed to inhibit production of all forms of a protein involved in the genetic brain disorder. Isis will get $30 million upfront and as much as $362 million in licensing and milestone fees plus sales royalties on drugs arising from the collaboration.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX